Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer.
To extend and improve the life of patients by directing the immune system against the core of cancer.
We will provide universally accessible solutions.
European patent approval for UV1 – 25.06.2019
Ultimovacs is developing a universal cancer vaccine applicable across a broad spectrum of cancer types.
Lead product tested in three clinical trials, strong results justifies the initiation of a registration trial.